drugset
drugset / Trial / NCT01080365

Study Comparing Two Different Tablet Formulations Of Bosutinib Under Fed Conditions

NCT01080365 ↗

Phase 1 Completed 31 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedCrossoverOpen-labelTreatment

Summary

Study comparing 2 formulations of bosutinib in healthy subjects.

Timeline

Start
2010-02
Primary completion
2010-03
Completion
2010-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Bosutinib Small molecule 500 mg Oral

Indications

No indication recorded.